ALHC
Alignment Healthcare, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
13.20
▲ 0.27 (2.09%)
MARKET · —
Price
Open
13.19
Prev close
12.93
Day high
13.32
Day low
12.93
Volume
2.22M
Market cap
$2.73B
P/E (TTM)
69.26
52W range
12.70 – 25.12
Trailing performance
Returnvs SPY
1W
-5.73%
-4.4%
1M
-34.20%
-37.9%
3M
-19.61%
-22.7%
6M
-36.12%
-47.2%
YTD
-33.37%
-45.7%
1Y
-12.38%
-32.4%
3Y
+100.00%
+25.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$2.73B
Enterprise value$2.36B
Revenue (TTM)$4.58B
Gross profit$574.42M
EBITDA$87.42M
Net income$40.70M
EPS (TTM)$0.19
Free cash flow$188.58M
Total cash$701.71M
Total debt$330.50M
Book value / share$1.28
Shares outstanding207.44M
Float187.82M
Short % of float10.92%
Dividend yield—
Beta (5Y)1.13
Valuation & profitability ratios
Trailing P/E69.26
Forward P/E17.49
PEG ratio—
Price / sales—
Price / book10.28
EV / revenue0.52
EV / EBITDA26.98
Gross margin12.55%
Operating margin3.15%
Profit margin0.89%
Return on equity20.04%
Return on assets3.07%
Debt / equity124.66
Current ratio1.70
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $3.95B | $2.70B | $1.82B | $1.43B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$724.00K | -$128.03M | -$148.02M | -$149.55M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$724.00K | -$128.03M | -$148.02M | -$149.55M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.20 | 0.25 | +24.4% |
| Mar 2026 | 0.09 | 0.12 | +38.7% |
| Dec 2025 | -0.08 | -0.00 | +98.2% |
| Sep 2025 | -0.01 | 0.10 | +1,081.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.06 | 4 | $1.31B | +32.1% |
| Next quarter | 0.05 | 4 | $1.33B | +31.5% |
| Current year | 0.50 | 4 | $5.21B | +32.1% |
| Next year | 0.75 | 4 | $6.50B | +24.6% |
Analyst targets & ownership
Mean target$24.08
High target$30.00
Low target$16.00
Implied upside82.40%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy3 / 9
Hold2
Sell / Strong sell0 / 0
Held by insiders2.77%
Held by institutions115.91%
Institutions holding433
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
-1.37M
Net selling
Buy transactions
24
1.44M shares
Sell transactions
32
2.81M shares
Net transactions
+56
Buys less sells
Sell : buy shares
2.0 : 1
Mixed
Insider-held shares
5.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 14, 26 | MARONEY DAWN CHRISTINE President |
SELL | 5.00K | $70.00K | Direct |
| Aug 10, 26 | KAO JOHN Chief Executive Officer |
SELL | 298.00K | $4.14M | Indirect |
| Jul 15, 26 | MARONEY DAWN CHRISTINE President |
CONVERSION | 152.07K | $1.38M | Direct |
| Jul 15, 26 | MARONEY DAWN CHRISTINE President |
SELL | 177.07K | $3.69M | Direct |
| Jul 10, 26 | KAO JOHN Chief Executive Officer |
SELL | 298.00K | $5.92M | Indirect |
| Jul 1, 26 | KONOWIECKI JOSEPH S Officer and Director |
SELL | 25.00K | $600.00K | Direct |
| Jul 1, 26 | HOCHRADEL SHANE J Chief Operating Officer |
STOCK | 87.72K | $0 | Direct |
| Jun 26, 26 | KONOWIECKI JOSEPH S Officer and Director |
SELL | 25.00K | $575.00K | Direct |
| Jun 18, 26 | KONOWIECKI JOSEPH S Officer and Director |
SELL | 25.00K | $550.00K | Direct |
| Jun 15, 26 | MARONEY DAWN CHRISTINE President |
SELL | 30.00K | $586.42K | Direct |
| Jun 12, 26 | KIM HYONG J Officer |
SELL | 35.95K | $713.95K | Direct |
| Jun 11, 26 | KONOWIECKI JOSEPH S Officer and Director |
SELL | 25.00K | $525.00K | Direct |
| Jun 10, 26 | KAO JOHN Chief Executive Officer |
SELL | 298.00K | $6.07M | Indirect |
| Jun 3, 26 | KONOWIECKI JOSEPH S Officer and Director |
STOCK | 122.81K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FREEMAN ROBERT THOMAS |
Chief Financial Officer | 1.56M | Sale |
GENERAL ATLANTIC ALN HLTH, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
GENERAL ATLANTIC L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
KAO JOHN |
Chief Executive Officer | — | Sale |
KARDES HAKAN |
Chief Executive Officer | 678.99K | Sale |
KIM HYONG J |
Officer | 331.75K | Sale |
KONOWIECKI JOSEPH S |
Officer and Director | 1.10M | Sale |
MARONEY DAWN CHRISTINE |
President | 917.31K | Sale |
MCCLELLAN MARK B |
Director | 370.53K | Stock Award(Grant) |
SCAVO ROBERT L |
Chief Technology Officer | 487.69K | Sale |
Moving averages & technicals
SMA 10
13.35
-1.11% from price
SMA 20
14.59
-9.81% from price
SMA 50
18.73
-29.73% from price
SMA 100
18.63
-29.13% from price
SMA 200
19.03
-30.84% from price
EMA 12
13.78
-4.18% from price
EMA 26
15.43
-14.42% from price
EMA 50
16.94
-22.10% from price
RSI (14)
33.3
Neutral
MACD (12,26,9)
-1.65
Hist 0.05
ATR (14)
0.69
5.23% of price
Realised vol 30D
80.7%
Annualised
Bollinger upper
18.63
20, 2σ
Bollinger lower
10.56
20, 2σ
50 / 200 cross
Death
18.73 vs 19.03
Trend bias
Below 200
-30.84%
Risk profile
Beta vs SPY
0.32
Less volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
80.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-48.0%
Peak to trough
Max drawdown 5Y
-80.4%
Peak to trough
ATR 14
0.69
5.23% of price
Beta (reported)
1.13
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
52.30
Put-heavy session
Put / call open interest
3.46
Positioning, not flow
Max pain
15.00
+14.0% from spot
ATM implied vol
73.2%
Nearest strike to spot
Skew (10% OTM)
+4.8%
Puts bid over calls
Call volume
10
Contracts, this expiry
Put volume
523
Contracts, this expiry
Heaviest call OI
15.00
151 contracts
Heaviest put OI
10.00
632 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · 2d ago
1 Profitable Stock for Long-Term Investors and 2 We Brush Off
StockStory · 7d ago
1 Cash-Heavy Stock on Our Buy List and 2 We Ignore
StockStory · 8d ago
2 Russell 2000 Stocks to Target This Week and 1 We Turn Down
StockStory · 10d ago
Alignment Healthcare Insider Sold Shares Worth $4,136,776, According to a Recent SEC Filing
MT Newswires · 11d ago
Can ALHC's Raised 2026 Outlook Offset Heavier Second-Half Spending?
Zacks · 15d ago
Is ALHC Stock a Buy as Fast Growth Clashes With Premium Valuation?
Zacks · 16d ago
Is Alignment Healthcare (ALHC) Still Undervalued As Lawsuit Driven Accounting Questions Grow?
Simply Wall St. · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.